DE69332222D1 - Enythropoietin enthaltendes arzneimittelabgabesystem - Google Patents

Enythropoietin enthaltendes arzneimittelabgabesystem

Info

Publication number
DE69332222D1
DE69332222D1 DE69332222T DE69332222T DE69332222D1 DE 69332222 D1 DE69332222 D1 DE 69332222D1 DE 69332222 T DE69332222 T DE 69332222T DE 69332222 T DE69332222 T DE 69332222T DE 69332222 D1 DE69332222 D1 DE 69332222D1
Authority
DE
Germany
Prior art keywords
enythropoietin
dispensing system
drug dispensing
containing drug
zein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332222T
Other languages
English (en)
Other versions
DE69332222T2 (de
DE69332222T3 (de
Inventor
Howard Bernstein
Edith Mathiowitz
Eric Morrel
Avram Brickner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Alkermes Controlled Therapeutics Inc
Original Assignee
Alkermes Inc
Alkermes Controlled Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25386613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69332222(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Inc, Alkermes Controlled Therapeutics Inc filed Critical Alkermes Inc
Publication of DE69332222D1 publication Critical patent/DE69332222D1/de
Publication of DE69332222T2 publication Critical patent/DE69332222T2/de
Application granted granted Critical
Publication of DE69332222T3 publication Critical patent/DE69332222T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE69332222T 1992-06-11 1993-06-09 Enythropoietin enthaltendes arzneimittelabgabesystem Expired - Fee Related DE69332222T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88530792A 1992-06-11 1992-06-11
US885307 1992-06-11
PCT/US1993/005497 WO1993025221A1 (en) 1992-06-11 1993-06-09 Erythropoietin drug delivery system

Publications (3)

Publication Number Publication Date
DE69332222D1 true DE69332222D1 (de) 2002-09-26
DE69332222T2 DE69332222T2 (de) 2003-03-20
DE69332222T3 DE69332222T3 (de) 2007-05-10

Family

ID=25386613

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332222T Expired - Fee Related DE69332222T3 (de) 1992-06-11 1993-06-09 Enythropoietin enthaltendes arzneimittelabgabesystem

Country Status (10)

Country Link
EP (1) EP0644771B2 (de)
JP (1) JPH07507806A (de)
AT (1) ATE222500T1 (de)
AU (2) AU680422B2 (de)
CA (1) CA2136434C (de)
DE (1) DE69332222T3 (de)
DK (1) DK0644771T4 (de)
ES (1) ES2181691T5 (de)
PT (1) PT644771E (de)
WO (1) WO1993025221A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
DE69329295T2 (de) 1992-12-02 2001-03-15 Alkermes Inc Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
WO1995024929A2 (en) * 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
FR2718642B1 (fr) * 1994-04-15 1996-07-12 Pf Medicament Microsphères biodégradables à libération contrôlée et leur procédé de préparation.
US5783214A (en) * 1994-06-13 1998-07-21 Buford Biomedical, Inc. Bio-erodible matrix for the controlled release of medicinals
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
EA001220B1 (ru) 1995-06-07 2000-12-25 Глаксо Груп Лимитед Пептид или пептидомиметик, который связывается с рецептором тромбоэтина, фармацевтическая композиция и способ лечения
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP0850051A2 (de) * 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Mittel zur verzögerten freisetzung eines wirkstoffs
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
GB2316316A (en) * 1996-08-23 1998-02-25 Int Centre Genetic Eng & Bio Sustained release of erythropoietin from microspheres
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
IT1293088B1 (it) * 1997-07-10 1999-02-11 Isi Ist Sierovaccinogeno Ital Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in
GB9817470D0 (en) * 1998-08-11 1998-10-07 Andaris Ltd Pharmaceutical formulation
DE19856432A1 (de) 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
US20010008627A1 (en) 1999-01-22 2001-07-19 Soll David R. Hiv-encoded chemoattractant
US6284283B1 (en) 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
CA2387805C (en) 1999-11-18 2012-08-28 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
US6974592B2 (en) 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
NZ566812A (en) 2002-09-18 2009-07-31 Ortho Mcneil Pharm Inc Methods of increasing platelet and hematopoietic stem cell production
EP1852441B1 (de) 2002-09-24 2012-03-28 The Burnham Institute Mittel zur Modulierung der EPH-Rezeptor-Aktivität
EP1575561B1 (de) 2002-11-04 2010-06-09 Ocean Nutrition Canada Limited Mikrokapseln mit mehrfachen hüllen und verfahren zu deren herstellung
DE10303584A1 (de) * 2003-01-30 2004-08-12 Stauss, Robert, Dr. Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7576056B2 (en) 2003-08-28 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
CN1856296A (zh) * 2003-09-30 2006-11-01 阿库斯菲尔公司 可注射的、口服、或局部用缓释药物制剂
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US8034450B2 (en) 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
US9968120B2 (en) 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
EP2040682B1 (de) 2006-06-05 2017-07-26 DSM Nutritional Products AG Mikrokapseln mit verbesserten ummantelungen
EP2046951B1 (de) 2006-07-05 2011-10-26 Catalyst Biosciences, Inc. Protease-screening-verfahren und dadurch identifizierte proteasen
CN103536579B (zh) 2007-01-10 2019-08-20 帝斯曼营养品股份公司 素食的微胶囊
DK2222327T3 (en) * 2007-12-28 2017-05-15 Augustinus Bader TOPICAL USE AND FORMULATION OF ERYTHROPOIETIN FOR HEALTH CARE
MX347229B (es) 2012-01-26 2017-04-19 Christopher J Soares Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
WO2015136527A1 (en) 2014-03-10 2015-09-17 Health Corporation - Rambam Heparanase inhibitory peptides and use thereof for treating clinical pathologies
EP3334418B1 (de) * 2015-08-10 2023-06-07 The Trustees of Princeton University Nanoverkapselung mit grasmaterialien und anwendungen davon
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
IL265099B1 (en) 2016-09-02 2024-05-01 Christopher J Soares Medicinal compositions containing an effective amount of a calcitonin gene-related peptide (CGRP) receptor antagonist, or a pharmaceutically acceptable salt thereof, for the treatment of glaucoma
JP7481252B2 (ja) 2017-07-26 2024-05-10 ヤンセン ファーマシューティカ エヌ．ベー． 標的放射線治療誘発性血管完全性を保護する方法
EP3914281A1 (de) 2019-01-25 2021-12-01 Janssen Pharmaceutica NV Verfahren für die verbesserung des schutzes gegen organ- und gefässverletzungen, hämatopoetische wiederherstellung und überleben in reaktion auf eine ganzkörperabstrahlung/chemische ganzkörperexposition
US20200237871A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
KR20210120037A (ko) 2019-01-25 2021-10-06 잔센파마슈티카엔.브이. 수포제 및 가성 가스의 독성 영향 경감 방법
IL311797A (en) 2021-10-01 2024-05-01 Albert Einstein College Of Medicine Methods for increasing stem cell production
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) † 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
SE459005B (sv) † 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5057317A (en) † 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
WO1989003678A1 (en) * 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
JPH04124127A (ja) * 1990-09-14 1992-04-24 Chugai Pharmaceut Co Ltd マイクロカプセル型徐放性製剤及びその製造法
EP0565618A4 (en) * 1991-01-03 1994-06-29 Alkermes Inc Stabilization of proteins by cationic biopolymers
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres

Also Published As

Publication number Publication date
ES2181691T3 (es) 2003-03-01
PT644771E (pt) 2002-12-31
EP0644771A1 (de) 1995-03-29
ATE222500T1 (de) 2002-09-15
AU4630893A (en) 1994-01-04
AU4275597A (en) 1998-01-15
DE69332222T2 (de) 2003-03-20
CA2136434A1 (en) 1993-12-23
AU698016B2 (en) 1998-10-22
DK0644771T4 (da) 2006-12-27
DE69332222T3 (de) 2007-05-10
EP0644771B1 (de) 2002-08-21
AU680422B2 (en) 1997-07-31
JPH07507806A (ja) 1995-08-31
WO1993025221A1 (en) 1993-12-23
ES2181691T5 (es) 2007-10-01
DK0644771T3 (da) 2002-12-16
EP0644771B2 (de) 2006-12-06
CA2136434C (en) 2008-12-02

Similar Documents

Publication Publication Date Title
DE69332222T2 (de) Enythropoietin enthaltendes arzneimittelabgabesystem
PT98397A (pt) Processo para a preparacao de microcapsulas para administracao de uma composicao farmaceutica com libertacao controlada duma proteina ou dum polipeptido mediante integracao com um polimero hidrofobico biodegradavel
NO884474D0 (no) Implanterbart, biologisk nedbrytbart virkestoff-frigjoeringssystem.
PT984774E (pt) Microesferas de libertacao controlada, com retencao gastrica, para uma administracao de drogas melhorada
FI872481A (fi) Kiinteä, hallitusti vapauttava lääkeaineen kantoaineena käytettävä matriisi
DK288987A (da) Et afgivelsessystem til doseringsformerne forhalet afgivelse, samt dettes fremstilling
BR9404330A (pt) Dispositivo para misturar uma composição farmacêutica com um outro agente, processo para preparar um preparado farmacêutico mediante a mistura de uma composição farmacêutica com um agente, e, processo para a aplicação oral de um preparado farmacêutico.
ATE258043T1 (de) Langsam freisetzende zubereitung für bioaktive substanz mit einer sauren gruppe
FR2683146B1 (fr) Compositions pharmaceutiques a liberation reglee de la substance medicamenteuse.
BR8804074A (pt) Polimero com unidades recorrentes,composicao estabilizante,processo para a preparacao de um estabilizante,e,composicao polimerica
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
BR0210631A (pt) Composição farmacêutica de liberação prolongada
DE68916357T2 (de) Kern-Schale-Polymer, Zusammensetzung und Formteile davon.
FI913426A0 (fi) Katalysatorer med staellen som kombinerar med antikropp innehaollande polyvalent metalljon.
DE60001717D1 (de) Mikrokapseln mit verzögerter freisetzung von wirkstoffen
MX9205982A (es) Agente para la preparacion de fibras, degradable biologicamente.
BR9916378A (pt) Misturas de polìmeros com agentes de desmoldagem
NO953647D0 (no) Veterinær-medikament med forlenget frigjöring
MX9200400A (es) Composicion farmaceutica que contiene polimeros aromaticos biologicamente activos
ATE77749T1 (de) Coccidiozide mittel.
FR2739563B1 (fr) Seringue de securite a usage unique, dont la canule d'aiguille se retracte automatiquement et entierement apres le premier usage
ES2043896T3 (es) Procedimiento para la preparacion de derivados de tetrahidropiridina.
RU97115826A (ru) Способ профилактики нагноений ран промежности

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8339 Ceased/non-payment of the annual fee